Cargando…
Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713-721.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
American Society of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929931/ https://www.ncbi.nlm.nih.gov/pubmed/31265499 http://dx.doi.org/10.1182/blood-2016-05-717777 |
Ejemplares similares
-
Zhang X, Dia R, Li W, et al. Abnormalities of follicular helper T-cell number and function in Wiskott-Aldrich syndrome. Blood. 2016;127(25):3180-3191.
Publicado: (2020) -
De Domenico I, Vaughn MB, Yoon D, Kushner JP, Ward DM, Kaplan J. Zebrafish as a model for defining the functional impact of mammalian ferroportin mutations. Blood. 2007;110(10):3780–3783.
Publicado: (2012) -
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
por: Maouche, Nadjoua, et al.
Publicado: (2022) -
Hungría : Tradición y cultura /
por: Salinas, Martha Isabel -
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)